Joseph H. Korn

Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo‐controlled phase I/II trial of CAT‐192

Christopher P. Denton, Peter A. Merkel, Daniel E. Furst et al. · Arthritis & Rheumatism · 2006 · 451 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +13

Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon

Peter A. Merkel, Karen Herlyn, Richard W. Martin et al. · Arthritis & Rheumatism · 2002 · 334 citations

Medicine, Clinical Sciences, Internal Medicine +15

Recombinant Human Relaxin in the Treatment of Scleroderma

James R. Seibold, Joseph H. Korn, Robert W. Simms et al. · Annals of Internal Medicine · 2000 · 266 citations

Medicine, Dermatology, Pharmacotherapy +6

Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study

Fredrick M. Wigley, Joseph H. Korn, Mary Ellen Csuka et al. · Arthritis & Rheumatism · 1998 · 199 citations

Medicine, Internal Medicine, Pharmacotherapy +11

Role of apoptosis and transforming growth factor β1 in fibroblast selection and activation in systemic sclerosis

Ante Jelaska, Joseph H. Korn · Arthritis & Rheumatism · 2000 · 161 citations

Life Sciences, Cell Biology, Pathology +16